IDH1 and central nervous system cancer: To this point, the National Comprehensive Cancer Network (NCCN) guidelines list ivosidenib – an IDH1 inhibitor- as a treatment option for recurrent IDH1 mutant grade II gliomas and in certain circumstances grade III and IV gliomas (Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.2.2024.